Participants deemed at low risk for harboring PCa (PSA < 1.5 ng/mL) are re-invited after a prolonged screening interval of 5 years, whereas participants deemed at higher, intermediate risk for harboring PCa (PSA 1.5–2.99 ng/mL) undergo more frequent, biennial PSA screening. The gene discussed is KLK3; the disease is posterior cortical atrophy.